{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:07:36Z","timestamp":1790741256960,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.curtheres.2025.100818","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T07:39:37Z","timestamp":1765870777000},"page":"100818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications"],"prefix":"10.1016","volume":"104","author":[{"given":"Jingjing","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Argon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ragueneau-Majlessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2025.100818_bib0001","unstructured":"ICH Guideline M12 on drug interaction studies. 2024. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-ich-guideline-m12-drug-interaction-studies-step-2b_en.pdf (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0002","unstructured":"FDA Guidance for Industry. In vitro drug interaction studies - Cytochrome P450 enzyme- and transporter-mediated drug interactions. 2020. Available online: \u200bhttps:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-101767646-pdf (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0003","unstructured":"FDA Guidance for Industry: Clinical drug interaction studies - Cytochrome P450 enzyme- and transporter-mediated drug interactions. 2020. Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0004","unstructured":"EMA\u2019s Guideline on the investigation of drug interactions. 2012. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions_en.pdf (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0005","unstructured":"MHLW\u2019s guideline on drug interaction for drug development and appropriate provision of information. Available online: https:\/\/www.mhlw.go.jp\/web\/t_doc?dataId=00tc3525&dataType=1 (accessed June 23, 2025)."},{"issue":"1","key":"10.1016\/j.curtheres.2025.100818_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.121.000401","article-title":"Pharmacokinetic Drug-drug interactions with drugs approved by the U.S. Food and Drug Administration in 2020: mechanistic understanding and clinical recommendations","volume":"50","author":"Yu","year":"2022","journal-title":"Drug Metab. Disp."},{"key":"10.1016\/j.curtheres.2025.100818_bib0007","unstructured":"FDA, Crinecerfont (CRENESSITY) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/218808Orig1s000,218820Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0008","unstructured":"FDA, Deuruxolitinib (LEQSELVI) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217900Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0009","unstructured":"FDA, Ensifentrine (OHTUVAYRE) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217389Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0010","unstructured":"FDA, Lazertinib (LAZCLUZE) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/219008Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0011","unstructured":"FDA, Mavorixafor (XOLREMDI) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/218709Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0012","unstructured":"FDA, Resmetirom (REZDIFFRA) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217785Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0013","unstructured":"FDA, Revumenib (REVUFORJ) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/218944Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0014","unstructured":"FDA, Seladelpar (LIVDELZI) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217899Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0015","unstructured":"FDA, Sofpironium (SOFDRA) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217347Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0016","unstructured":"FDA, Vorasidenib (VORANIGO) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/218784Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0017","unstructured":"FDA, Vanzacaftor, tezacaftor, and deutivacaftor (ALYFTREK) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/218730Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0018","unstructured":"FDA, Sulopenem etzadroxil and probenecid (ORLYNVAH) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/213972Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0019","unstructured":"FDA, Vadadustat (VAFSEO) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/215192Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0020","unstructured":"FDA, Ensartinib (ENSACOVE) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/218171Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0021","unstructured":"FDA, Acoramidis (ATTRUBY) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/216540Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0022","unstructured":"FDA, Cefepime and enmetazobactam (EXBLIFEP) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/216165Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0023","unstructured":"FDA, Givinostat (DUVYZAT) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217865Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0024","unstructured":"FDA, Elafibranor (IQIRVO) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/218860Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0025","unstructured":"FDA, Tovorafenib (OJEMDA) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217700Orig1s000,%20218033Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0026","unstructured":"FDA, Xanomeline and trospium (COBENFY) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/216158Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0027","unstructured":"FDA, Inavolisib (ITOVEBI) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/219249Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0028","unstructured":"FDA, Arimoclomol (MIPLYFFA) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/214927Orig1s000TOC.cfm (accessed 23 June 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0029","unstructured":"FDA, Danicopan (VOYDEYA) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/218037Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0030","unstructured":"FDA, Levacetylleucine (AQNEURSA) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/219132Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0031","unstructured":"FDA, Ceftobiprole medocaril (ZEVTERA) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/218275Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0032","unstructured":"FDA, Sparsentan (FILSPARI) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/216403Orig1s000TOC.cfm (accessed June 23, 2025)."},{"key":"10.1016\/j.curtheres.2025.100818_bib0033","unstructured":"FDA, Trofinetide (DAYBUE) product label and NDA reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/217026Orig1s000TOC.cfm (accessed June 23, 2025)."},{"issue":"6","key":"10.1016\/j.curtheres.2025.100818_bib0034","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/jcph.6183","article-title":"Clinical assessment of drug transporter inhibition using biomarkers: review of the literature (2015-2024)","volume":"65","author":"Rodrigues","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2025.100818_bib0035","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1124\/dmd.123.001285","article-title":"Progress in the quantitative assessment of transporter-mediated drug\u2013drug interactions using endogenous substrates in clinical studies","volume":"51","author":"Mochizuki","year":"2023","journal-title":"Drug Metab. Dispos."}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X25000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X25000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:20:40Z","timestamp":1781151640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X25000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":35,"alternative-id":["S0011393X25000438"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2025.100818","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2025.100818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100818"}}